Alternating electric field therapy

Novocure Announces Preliminary Full Year and Fourth Quarter 2021 Net Revenues and Provides Company Update

Retrieved on: 
Monday, January 10, 2022
Biotechnology, Health, General Health, Radiology, Pharmaceutical, Oncology, Other Science, Research, Infectious Diseases, Science, Clinical Trials, Liver cancer, Large-cell lung carcinoma, Alternating electric field therapy, Prescription, Data monitoring committee, Medicare, Neoplasm, Disclosure, LinkedIn, Regulation Fair Disclosure, Total, DMC, Cancer, Patient, Investment, Ovarian cancer, Adult, NASDAQ, EST, Forward-looking statement, U.S. Securities and Exchange Commission, Annual report, Survival, Pancreatic cancer, Partnership, Private Securities Litigation Reform Act, COVID-19, Twitter, Webcast, Glioblastoma, Regulation, Stomach, EMEA, Adoption, Mesothelioma, Medical imaging, Pharmaceutical industry, Fine chemical, Audit, EU

Total preliminary net revenues for the year ended December 31, 2021, were $535.0 million, up 8% over the prior year.

Key Points: 
  • Total preliminary net revenues for the year ended December 31, 2021, were $535.0 million, up 8% over the prior year.
  • Total preliminary net revenues for the fourth quarter 2021 were $133.2 million.
  • Preliminary fourth quarter 2021 net revenues from the United States, EMEA and Japan contributed $92.0 million, $26.5 million and $8.8 million, respectively.
  • In the fourth quarter 2021, Novocure initiated contract negotiations with several large German payers that drove an update to the net revenue recognized per active patient, which negatively impacted fourth quarter revenue by approximately $4.0 million.

Novocure to Participate in the 40th Annual J.P. Morgan Healthcare Conference

Retrieved on: 
Tuesday, January 4, 2022
Biotechnology, Other Health, Health, Pharmaceutical, Oncology, COVID-19, Alternating electric field therapy, Large-cell lung carcinoma, Ovarian cancer, Investor relations, Disclosure, Private Securities Litigation Reform Act, Patient, Pancreatic cancer, Adult, Forward-looking statement, Cancer, Liver cancer, U.S. Securities and Exchange Commission, Conference, Twitter, Mesothelioma, Annual report, EST, Survival, NASDAQ, Regulation, LinkedIn, Glioblastoma, Regulation Fair Disclosure, Stomach

Novocure (NASDAQ: NVCR) announced today it will participate in the 40th Annual J.P. Morgan Virtual Healthcare Conference on January 10 through January 13, 2022.

Key Points: 
  • Novocure (NASDAQ: NVCR) announced today it will participate in the 40th Annual J.P. Morgan Virtual Healthcare Conference on January 10 through January 13, 2022.
  • Mr. Doyle and Ashley Cordova, Novocures Chief Financial Officer, will also participate in one-on-one meetings with investors throughout the event.
  • Novocure has used, and intends to continue to use, its Investor Relations website as a means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD.
  • Novocures commercialized products are approved in certain countries for the treatment of adult patients with glioblastoma and malignant pleural mesothelioma.

Novocure Signs Agreement to Acquire and Construct Building in Downtown Portsmouth, New Hampshire

Retrieved on: 
Tuesday, December 7, 2021
Oncology, Health, Commercial Building & Real Estate, Construction & Property, Pharmaceutical, Biotechnology, U.S. Securities and Exchange Commission, Physician, Pancreatic cancer, Twitter, Forward-looking statement, Liver cancer, Alternating electric field therapy, Ovarian cancer, Culture, Growth, Workforce, Private Securities Litigation Reform Act, Stomach, Patient, Cancer, Large-cell lung carcinoma, History, Mesothelioma, COVID-19, Adult, Survival, NASDAQ, LinkedIn, Sale, Annual report, Glioblastoma, Pharmaceutical industry

Novocure (NASDAQ: NVCR) today announced that the company has signed a purchase and sale agreement to acquire and construct an office building at 64 Vaughan Mall, in the heart of downtown Portsmouth, New Hampshire.

Key Points: 
  • Novocure (NASDAQ: NVCR) today announced that the company has signed a purchase and sale agreement to acquire and construct an office building at 64 Vaughan Mall, in the heart of downtown Portsmouth, New Hampshire.
  • Novocure established its U.S. operations in Portsmouth in 2006, and has grown from one employee in Portsmouth to more than 300 employees today.
  • Novocures U.S. roots began in Portsmouth more than 15 years ago, said William Doyle, Novocures Executive Chairman.
  • At the time, we were only beginning, with our cancer therapy just starting to go through clinical trials.

Novocure Announces 4th Annual AACR-Novocure Grants for Tumor Treating Fields Research Program

Retrieved on: 
Monday, December 6, 2021
Health, Science, Research, Clinical Trials, Oncology, Research, Patient, Skin, Pancreatic cancer, Ovarian cancer, Annual report, Private Securities Litigation Reform Act, AACR, Forward-looking statement, Alternating electric field therapy, Toxicity, Large-cell lung carcinoma, Partnership, Cancer, Neoplasm, Program, COVID-19, Glioblastoma, U.S. Securities and Exchange Commission, Liver cancer, Survival, Twitter, Adult, American Association for Cancer Research, Science, Learning, LinkedIn, American Association, Stomach, Association, NASDAQ, Fundamental, Mesothelioma, Pharmaceutical industry, Tumor Treating Fields, Novocure, TUMOR TREATING FIELDS, NOVOCURE

Novocure (NASDAQ: NVCR) today announced the 4th Annual AACR-Novocure Grants for Tumor Treating Fields Research Program.

Key Points: 
  • Novocure (NASDAQ: NVCR) today announced the 4th Annual AACR-Novocure Grants for Tumor Treating Fields Research Program.
  • The research grants will include five AACR-Novocure Tumor Treating Fields Research Grants and two AACR-Novocure Career Development Awards for Tumor Treating Fields Research.
  • Novocure and the AACR encourage applicants to focus their proposals on translational approaches, promoting the transition of in vitro work into in vivo systems; combination therapies involving Tumor Treating Fields; and bringing treatments involving Tumor Treating Fields to the clinic.
  • To apply for the AACR-Novocure Grants for Tumor Treating Fields Research, visit www.aacr.org/funding .

Novocure to Participate in Two Upcoming Investor Conferences

Retrieved on: 
Tuesday, November 23, 2021
Health, Science, Research, Clinical Trials, Oncology, Patient, Investor relations, Disclosure, Pancreatic cancer, Ovarian cancer, Conference, Annual report, Private Securities Litigation Reform Act, Forward-looking statement, Alternating electric field therapy, Large-cell lung carcinoma, Cancer, Regulation, COVID-19, Glioblastoma, U.S. Securities and Exchange Commission, Liver cancer, EST, Survival, Twitter, Adult, LinkedIn, Stomach, NASDAQ, Mesothelioma, Regulation Fair Disclosure, Lithium

Novocure (NASDAQ: NVCR) announced today it will participate in two upcoming investor conferences.

Key Points: 
  • Novocure (NASDAQ: NVCR) announced today it will participate in two upcoming investor conferences.
  • William Doyle, Novocures Executive Chairman, and Ashley Cordova, Novocures Chief Financial Officer, will participate in the 33rd Annual 2021 Piper Sandler Healthcare Conference on November 30, 2021.
  • Novocures corporate presentation is updated periodically, and the current presentation can be accessed from the Investor Relations page of Novocures website, www.novocure.com/investor-relations .
  • Novocure has used, and intends to continue to use, its Investor Relations website as a means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD.

Novocure Announces Last Patient Enrolled in Phase 3 Pivotal LUNAR Trial of Tumor Treating Fields in Non-small Cell Lung Cancer

Retrieved on: 
Monday, November 22, 2021
Research, Clinical Trials, Biotechnology, Other Health, Health, General Health, Other Science, Science, Oncology, Patient, NSCLC, Skin, Pemetrexed, Pancreatic cancer, Docetaxel, Mesothelioma, Ovarian cancer, Disease, Lung cancer, Annual report, Private Securities Litigation Reform Act, Forward-looking statement, Alternating electric field therapy, Toxicity, Large-cell lung carcinoma, Courage, Cancer, Non-small-cell lung carcinoma, Neoplasm, Physician, COVID-19, Glioblastoma, U.S. Securities and Exchange Commission, Liver cancer, Survival, Twitter, Treatment of lung cancer, Adult, Radiation, Immunotherapy, LinkedIn, Stomach, NASDAQ, Fundamental, Standard of care, Pharmaceutical industry, Lung Cancer, Tumor Treating Fields, Novocure, LUNG CANCER, TUMOR TREATING FIELDS, NOVOCURE

Non-small cell lung cancer impacts nearly 200,000 patients every year in the U.S., and lung cancer is the leading cause of cancer-related death globally.

Key Points: 
  • Non-small cell lung cancer impacts nearly 200,000 patients every year in the U.S., and lung cancer is the leading cause of cancer-related death globally.
  • LUNAR will provide the first randomized dataset to evaluate increased survival when Tumor Treating Fields is used together with immunotherapy, versus immunotherapy alone.
  • Lung cancer is the most common cause of cancer-related death worldwide, and NSCLC accounts for approximately 85% of all lung cancers.
  • Novocure has ongoing or completed clinical trials investigating Tumor Treating Fields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer and ovarian cancer.

2-THE-TOP Phase 2 Trial Reports Positive Top-Line Results in Newly Diagnosed Glioblastoma

Retrieved on: 
Monday, November 15, 2021
Science, Other Science, Research, Pharmaceutical, Oncology, General Health, Health, Clinical Trials, Population, Progression-free survival, Cancer, COVID-19, Fundamental, Pembrolizumab, Thrombosis, Chemoradiotherapy, Safety, Toxic leukoencephalopathy, Temozolomide, Research, Forward-looking statement, HIV disease progression rates, Simpson, Annual general meeting, Large-cell lung carcinoma, Survival, Patient, Biopsy, Glioblastoma, Adult, SNO, Private Securities Litigation Reform Act, Neoplasm, Division, U.S. Securities and Exchange Commission, Pakistan Society of Neuro-Oncology, NASDAQ, GBM, Liver cancer, Society, Mutation, Seizure, Twitter, IDH, Spear, Mesothelioma, Pancreatic cancer, Alternating electric field therapy, University, McKnight Brain Institute, Stomach, Ovarian cancer, MGMT, Annual report, LinkedIn, Toxicity, Skin, Pharmaceutical industry, Medical imaging, EF-14, Tumor Treating Fields, Novocure, EF-14, TUMOR TREATING FIELDS, NOVOCURE

The results published today suggest a potential paradigm shift in how we approach treatment of patients with newly diagnosed glioblastoma.

Key Points: 
  • The results published today suggest a potential paradigm shift in how we approach treatment of patients with newly diagnosed glioblastoma.
  • We would like to thank Dr. Tran and the patients enrolled in the 2-THE-TOP trial for their ingenuity and courage.
  • The 2-THE-TOP trial is a phase 2 pilot trial designed for the treatment of patients with newly diagnosed GBM.
  • The EF-14 trial was a randomized, phase 3 pivotal trial which compared, post radiation, TTFields plus temozolomide versus temozolomide alone for the treatment of newly diagnosed GBM.

Novocure Announces Last Patient Enrolled in Phase 3 Pivotal INNOVATE-3 Trial of Tumor Treating Fields in Ovarian Cancer

Retrieved on: 
Thursday, October 28, 2021
Oncology, Health, Clinical Trials, Research, Pharmaceutical, Science, Woman, Death, Stomach, Ovarian cancer, Pancreatic cancer, Chromosome, Data monitoring committee, Quality of life, Diagnosis, Recurrence, Neoplasm, LinkedIn, Prognosis, Cancer, Disease, Cell division, Fundamental, Survival, Mitosis, Physician, Twitter, Patient, Private Securities Litigation Reform Act, NASDAQ, Paclitaxel, Liver cancer, Large-cell lung carcinoma, European Network of Transmission System Operators for Electricity, U.S. Securities and Exchange Commission, Adult, Protein, Glioblastoma, Annual report, Forward-looking statement, Standard of care, Cytoplasm, DMC, COVID-19, Skin, Cell, Alternating electric field therapy, Cell death, Microtubule, Population, Toxicity, Incidence, Mesothelioma, Pharmaceutical industry, Medical imaging, Ovarian Cancer, Tumor Treating Fields, Novocure, OVARIAN CANCER, TUMOR TREATING FIELDS, NOVOCURE

Novocure (NASDAQ: NVCR) today announced that the final patient has been enrolled in phase 3 pivotal INNOVATE-3 trial evaluating the efficacy of Tumor Treating Fields (TTFields) together with paclitaxel for treatment of patients with platinum-resistant ovarian cancer.

Key Points: 
  • Novocure (NASDAQ: NVCR) today announced that the final patient has been enrolled in phase 3 pivotal INNOVATE-3 trial evaluating the efficacy of Tumor Treating Fields (TTFields) together with paclitaxel for treatment of patients with platinum-resistant ovarian cancer.
  • INNOVATE-3 is a randomized, open-label study which was designed to enroll 540 adult patients with recurrent, platinum-resist ovarian cancer.
  • In the U.S., ovarian cancer ranks fifth in cancer deaths among women, with approximately 24,000 women diagnosed each year.
  • Novocure has ongoing or completed clinical trials investigating Tumor Treating Fields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer and ovarian cancer.

Novocure Announces 15 Presentations at the American Society for Radiation Oncology 2021 Annual Meeting

Retrieved on: 
Thursday, October 21, 2021
Health, Science, Radiology, Research, Oncology, Temozolomide, Stomach, Radiation, DNA replication, Pancreatic cancer, Annual general meeting, Research, Recurrence, Neoplasm, LinkedIn, Cancer, Sorafenib, Mesothelioma, Survival, Radiation therapy, Twitter, Partnership, Patient, Private Securities Litigation Reform Act, NASDAQ, Spinal cord, Liver cancer, Large-cell lung carcinoma, Ovarian cancer, U.S. Securities and Exchange Commission, GBM, Chemoradiotherapy, Hepatocellular carcinoma, CDT, Concurrency, Glioblastoma, Adult, Annual report, Forward-looking statement, COVID-19, Lung cancer, Alternating electric field therapy, ASTRO, Cell death, Astrocytoma, American Society for Radiation Oncology, Society, DNA, Medical imaging, Communications satellite

Novocure (NASDAQ: NVCR) today announced 15 presentations on Tumor Treating Fields (TTFields) will be featured at the American Society for Radiation Oncology (ASTRO) 2021 Annual Meeting from Oct. 24 to Oct. 27 in Chicago.

Key Points: 
  • Novocure (NASDAQ: NVCR) today announced 15 presentations on Tumor Treating Fields (TTFields) will be featured at the American Society for Radiation Oncology (ASTRO) 2021 Annual Meeting from Oct. 24 to Oct. 27 in Chicago.
  • External authors prepared five of the presentations, three of which include new data, reflecting continued interest in Novocures proprietary TTFields platform within the radiation oncology community.
  • We and our partners are excited to present and see a variety of research on Tumor Treating Fields at ASTROs 2021 Annual Meeting, said Dr. Ely Benaim, Novocures Chief Medical Officer.
  • We look forward to participating in the exchange of scientific information at one of the premier meetings for radiation oncologists.

Zai Lab and Novocure Announce Last Patient Enrolled in Phase 2 Pilot Trial of Tumor Treating Fields Plus Chemotherapy as First-Line Treatment in Gastric Cancer in China

Retrieved on: 
Monday, October 4, 2021
Mortality, Cell death, Pancreatic cancer, Cytoplasm, Private Securities Litigation Reform Act, Overalls, Chromosome, Mesothelioma, Cell, Safety, Investment, Capecitabine, Protein, Glioblastoma, Microtubule, Degenerative disease, Health, U.S. Securities and Exchange Commission, LinkedIn, Adult, Infection, Twitter, Coronavirus, Ovarian cancer, Cell division, Survival, Incidence, EDGAR, Clinical trial, Mitosis, Annual report, NASDAQ, Cancer, Neoplasm, Toxicity, Alternating electric field therapy, Stomach, Large-cell lung carcinoma, Stomach cancer, HIV disease progression rates, Forward-looking statement, GLOBE, Oxaliplatin, Fundamental, Risk, Patient, XELOX, Liver cancer, COVID-19, Drug development, Data collection, Skin, Pharmaceutical industry, Medical imaging

SHANGHAI and St. Helier, JERSEY, Oct. 04, 2021 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), an innovative commercial-stage biopharmaceutical company, and Novocure (NASDAQ: NVCR), a global oncology company working to extend survival in some of the most aggressive forms of cancer, today announced that the final patient has been enrolled in a Novocure-sponsored phase 2 pilot trial conducted by Zai Lab evaluating the safety and efficacy of Tumor Treating Fields (TTFields) in combination with chemotherapy as a first-line treatment in patients with gastric adenocarcinoma. Final data collection is expected in the first half of 2022.

Key Points: 
  • This trial, conducted entirely in China, showcases Zais capabilities as we partner with Novocure to expand treatment options for gastric cancer patients in China.
  • The phase 2 pilot gastric cancer trial of TTFields has enrolled approximately 30 patients in Greater China.
  • We look forward to seeing results from this phase 2 pilot trial with our partner, Zai Lab, and to further exploring the potential of Tumor Treating Fields as a treatment for gastric cancer.
  • Novocure has ongoing or completed clinical trials investigating Tumor Treating Fields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer and ovarian cancer.